In support of this hypothesis, it has been shown that blocking CaV1.3 with a calcium channel antagonist, isradipine, afforded protection against neurodegeneration in the MPTP, 6-OHDA and rotenone rodent model of PD (Chan et al., 2007, 2010; Ilijic et al., 2011). Here, CACNA1D is linked to Parkinson disease.